172@29@17@243!~!172@29@0@53!~!|news|business|companies|alembic-cadilalupin-keep-pharma-coshigh-spirits-983783.html!~!news|moneycontrol|com!~!|controller|infinite_scroll_article.php!~!is_mobile=false
Moneycontrol
Subscribe to PRO at just Rs.33 per month. Use code SUPERPRO
Last Updated : Jul 08, 2016 03:48 PM IST | Source: CNBC-TV18

Alembic, Cadila & Lupin keep pharma cos in high spirits

An establishment inspection report for Alembic‘s Karakhadi API plant from the regulator is a big positive as API is one of the main drivers for the company, says Sarabjit Kaur Nangra of Angel Broking.

The week has ended on a positive note for pharmaceutical companies with many clearances coming through from the United States Food & Drug Association (US FDA).

Varun Goel of Motilal Oswal AMC believes that the Indian pharma sector has dealt with regulatory issues, and are competent enough to tackle them.

An establishment inspection report for Alembic’s Karakhadi API plant from the regulator is a big positive as API is one of the main drivers for the company, says Sarabjit Kaur Nangra of Angel Broking.

However, it won’t change valuations for the company.

On Cadila, Nangra says that the Establishment Inspection Report (EIR) approval is a big booster for its important Moraiya facility.

Recently, Cadila also signed an agreement with The Medicines Patent Pool for generic production of Bristol-Myers Squibb’s daclatasvir.

Nangra has a buy call on the stock, which has underperformed its peers in recent times.

Lupin
too received an EIR today for its Goa Plant for an enquiry in June 2015, which resolves its partial regulatory issues. Another minor observation for its API facility, however, is not big as the company’s focus on API is minimal.

Lupin is very attractively valued, says Nangra adding that the target for the stock is Rs 1800.
First Published on Jul 8, 2016 03:48 pm
Sections